Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Gastrointest Liver Physiol ; 297(6): G1147-62, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19808660

ABSTRACT

We tested the novel hypothesis that endogenous adenosine (eADO) activates low-affinity A3 receptors in a model of neurogenic diarrhea in the guinea pig colon. Dimaprit activation of H2 receptors was used to trigger a cyclic coordinated response of contraction and Cl(-) secretion. Contraction-relaxation was monitored by sonomicrometry (via intracrystal distance) simultaneously with short-circuit current (I(sc), Cl(-) secretion). The short interplexus reflex coordinated response was attenuated or abolished by antagonists at H2 (cimetidine), 5-hydroxytryptamine 4 receptor (RS39604), neurokinin-1 receptor (GR82334), or nicotinic (mecamylamine) receptors. The A1 agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) abolished coordinated responses, and A1 antagonists could restore normal responses. A1-selective antagonists alone [8-cyclopentyltheophylline (CPT), 1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine (PACPX), or 8-cyclopentyl-N(3)-[3-(4-(fluorosulfonyl)benzoyloxy)propyl]-xanthine (FSCPX)] caused a concentration-dependent augmentation of crypt cell secretion or contraction and acted at nanomolar concentrations. The A3 agonist N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) abolished coordinated responses and the A3 antagonist 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS1191) could restore and further augment responses. The IB-MECA effect was resistant to knockdown of adenosine A1 receptor with the irreversible antagonist FSCPX; the IC(50) for IB-MECA was 0.8 microM. MRS1191 alone could augment or unmask coordinated responses to dimaprit, and IB-MECA suppressed them. MRS1191 augmented distension-evoked reflex I(sc) responses. Adenosine deaminase mimicked actions of adenosine receptor antagonists. A3 receptor immunoreactivity was differentially expressed in enteric neurons of different parts of colon. After tetrodotoxin, IB-MECA caused circular muscle relaxation. The data support the novel concept that eADO acts at low-affinity A3 receptors in addition to high-affinity A1 receptors to suppress coordinated responses triggered by immune-histamine H2 receptor activation. The short interplexus circuit activated by histamine involves adenosine, acetylcholine, substance P, and serotonin. We postulate that A3 receptor modulation may occur in gut inflammatory diseases or allergic responses involving mast cell and histamine release.


Subject(s)
Adenosine/metabolism , Colon/metabolism , Enteric Nervous System/metabolism , Gastrointestinal Motility , Histamine/metabolism , Muscle, Smooth/metabolism , Neural Inhibition , Neurogenic Bowel/metabolism , Receptor, Adenosine A3/metabolism , Adenosine/analogs & derivatives , Adenosine/pharmacology , Animals , Chlorides/metabolism , Cimetidine/pharmacology , Colon/drug effects , Colon/immunology , Colon/innervation , Dihydropyridines/pharmacology , Dimaprit/pharmacology , Dose-Response Relationship, Drug , Enteric Nervous System/drug effects , Enteric Nervous System/physiopathology , Gastrointestinal Motility/drug effects , Guinea Pigs , Histamine Agonists/pharmacology , Histamine H2 Antagonists/pharmacology , In Vitro Techniques , Intestinal Secretions/metabolism , Male , Mecamylamine/pharmacology , Muscle Contraction , Muscle Relaxation , Muscle, Smooth/drug effects , Muscle, Smooth/immunology , Muscle, Smooth/innervation , Neural Inhibition/drug effects , Neurogenic Bowel/immunology , Neurogenic Bowel/physiopathology , Neurokinin-1 Receptor Antagonists , Nicotinic Antagonists/pharmacology , Piperidines/pharmacology , Propane/analogs & derivatives , Propane/pharmacology , Receptor, Adenosine A1/drug effects , Receptor, Adenosine A1/metabolism , Receptor, Adenosine A3/drug effects , Receptors, Histamine H2/drug effects , Receptors, Histamine H2/metabolism , Receptors, Neurokinin-1/metabolism , Reflex , Theophylline/analogs & derivatives , Theophylline/pharmacology , Xanthines/pharmacology
2.
Inflamm Bowel Dis ; 12(8): 766-89, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16917233

ABSTRACT

Adenosine A3 receptors (ADOA3Rs) are emerging as novel purinergic targets for treatment of inflammatory diseases. Our goal was to assess the protective effect of the ADOA3R agonist N(6)-(3-iodobenzyl)-adenosine-5-N-methyluronamide (IB-MECA) on gene dysregulation and injury in a rat chronic model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)--induced colitis. It was necessary to develop and validate a microarray technique for testing the protective effects of purine-based drugs in experimental inflammatory bowel disease. High-density oligonucleotide microarray analysis of gene dysregulation was assessed in colons from normal, TNBS-treated (7 days), and oral IB-MECA-treated rats (1.5 mg/kg b.i.d.) using a rat RNU34 neural GeneChip of 724 genes and SYBR green polymerase chain reaction. Analysis included clinical evaluation, weight loss assessment, and electron paramagnetic resonance imaging/spin-trap monitoring of free radicals. Remarkable colitis-induced gene dysregulation occurs in the most exceptional cluster of 5.4% of the gene pool, revealing 2 modes of colitis-related dysregulation. Downregulation occurs in membrane transporter, mitogen-activated protein (MAP) kinase, and channel genes. Upregulation occurs in chemokine, cytokine/inflammatory, stress, growth factor, intracellular signaling, receptor, heat shock protein, retinoid metabolism, neural, remodeling, and redox-sensitive genes. Oral IB-MECA prevented dysregulation in 92% of these genes, histopathology, gut injury, and weight loss. IB-MECA or adenosine suppressed elevated free radicals in ex vivo inflamed gut. Oral IB-MECA blocked the colitis-induced upregulation (90% of genes tested (33 of 37 genes). We conclude that our validated high-density oligonucleotide microarray analysis is a powerful technique for molecular gene dysregulation studies to assess the beneficial effects of purine-based or other drugs in experimental colitis. ADOA3R is new potential therapeutic target for inflammatory bowel disease.


Subject(s)
Adenosine A3 Receptor Agonists , Adenosine/analogs & derivatives , Colitis/drug therapy , Gene Expression Regulation/drug effects , Oligonucleotide Array Sequence Analysis , Adenosine/pharmacology , Adenosine/therapeutic use , Animals , Colitis/chemically induced , Colitis/enzymology , Colitis/genetics , Disease Models, Animal , Free Radicals/metabolism , Glutathione Peroxidase/metabolism , Polymerase Chain Reaction , Rats , Rats, Sprague-Dawley , Superoxide Dismutase/metabolism , Trinitrobenzenesulfonic Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...